The estimated Net Worth of Leaf Biopharma Opportunitie... is at least $9.11 Milion dollars as of 25 October 2023. Leaf Opportunitie owns over 1,543,500 units of Harpoon Therapeutics stock worth over $9,106,967 and over the last few years Leaf sold HARP stock worth over $0.
Leaf has made over 1 trades of the Harpoon Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Leaf bought 1,543,500 units of HARP stock worth $35,515,935 on 25 October 2023.
The largest trade Leaf's ever made was buying 1,543,500 units of Harpoon Therapeutics stock on 25 October 2023 worth over $35,515,935. On average, Leaf trades about 771,750 units every 0 days since 2023. As of 25 October 2023 Leaf still owns at least 395,783 units of Harpoon Therapeutics stock.
You can see the complete history of Leaf Opportunitie stock trades at the bottom of the page.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt a Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: